FR22C1053I2 - Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1 - Google Patents
Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1Info
- Publication number
- FR22C1053I2 FR22C1053I2 FR22C1053C FR22C1053C FR22C1053I2 FR 22C1053 I2 FR22C1053 I2 FR 22C1053I2 FR 22C1053 C FR22C1053 C FR 22C1053C FR 22C1053 C FR22C1053 C FR 22C1053C FR 22C1053 I2 FR22C1053 I2 FR 22C1053I2
- Authority
- FR
- France
- Prior art keywords
- abl1
- abl2
- bcr
- inhibiting
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 title 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 title 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 title 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647174P | 2012-05-15 | 2012-05-15 | |
US201361790967P | 2013-03-15 | 2013-03-15 | |
PCT/IB2013/053768 WO2013171639A1 (en) | 2012-05-15 | 2013-05-09 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR22C1053I1 FR22C1053I1 (fr) | 2022-12-16 |
FR22C1053I2 true FR22C1053I2 (fr) | 2023-11-10 |
Family
ID=48670630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR22C1053C Active FR22C1053I2 (fr) | 2012-05-15 | 2022-10-20 | Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1 |
Country Status (50)
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014026643B1 (pt) | 2012-04-26 | 2023-03-07 | Universite De Montreal | Derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica |
US9340537B2 (en) | 2012-05-15 | 2016-05-17 | Novatis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
BR112014027181A2 (pt) * | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 |
PL2900637T3 (pl) | 2012-05-15 | 2018-01-31 | Novartis Ag | Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns |
TR201807023T4 (tr) | 2012-05-15 | 2018-06-21 | Novartis Ag | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
JP6554037B2 (ja) | 2013-01-15 | 2019-07-31 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物 |
AU2014308703A1 (en) | 2013-08-23 | 2016-03-24 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors |
EP3064489A4 (de) * | 2013-11-01 | 2017-06-21 | Ube Industries, Ltd. | Aryloyl(oxy- oder amino-)pentafluorsulfanylbenzen-verbindung, pharmazeutisch unbedenkliches salz davon und prodrugs davon |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AU2015217221A1 (en) * | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
CN104478911A (zh) * | 2014-12-19 | 2015-04-01 | 成都安斯利生物医药有限公司 | 一种制备3-三氟甲基吡咯硼酸的方法 |
US20180000771A1 (en) * | 2015-01-13 | 2018-01-04 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
EP3964528A1 (de) | 2015-07-29 | 2022-03-09 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP4378957A2 (de) | 2015-07-29 | 2024-06-05 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen pd-1 |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
PL3370768T3 (pl) | 2015-11-03 | 2022-06-13 | Janssen Biotech, Inc. | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
WO2017186148A1 (en) * | 2016-04-29 | 2017-11-02 | Astar Biotech Llc | Novel heterocyclic compounds as tyrosine kinase bcr-abl inhibitors |
EP3507367A4 (de) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon |
WO2018060843A1 (en) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Surfactant systems for crystallization of organic compounds |
WO2018081372A1 (en) * | 2016-10-26 | 2018-05-03 | The University Of Georgia Research Foundation, Inc. | Methods of treatment for myeloid leukemia |
WO2018167803A1 (en) * | 2017-03-15 | 2018-09-20 | Sun Pharma Advanced Research Company Limited | Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JPWO2018216705A1 (ja) * | 2017-05-23 | 2020-03-26 | 国立大学法人京都大学 | 神経変性疾患の予防及び/又は治療剤 |
EP3642240A1 (de) | 2017-06-22 | 2020-04-29 | Novartis AG | Antikörpermoleküle gegen cd73 und verwendungen davon |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3737676B1 (de) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetalverbindungen und therapeutische verwendungen davon |
EP3781156A4 (de) * | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclische verbindungen |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
KR102618168B1 (ko) * | 2018-07-06 | 2023-12-27 | 일양약품주식회사 | 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물 |
KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
TW202110823A (zh) * | 2019-05-16 | 2021-03-16 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
US11236070B2 (en) * | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
GB201913110D0 (en) * | 2019-09-11 | 2019-10-23 | Benevolentai Bio Ltd | New compounds and methods |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
CN114728943A (zh) * | 2020-01-19 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 作为bcr-abl抑制剂的化合物 |
EP4096790A1 (de) | 2020-01-28 | 2022-12-07 | Teva Pharmaceuticals International GmbH | Feste formen von asciminib und herstellungsverfahren dafür |
US20230072528A1 (en) | 2020-02-05 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
CN111321200A (zh) * | 2020-02-28 | 2020-06-23 | 广州安镝声生物医药科技有限公司 | 一种细胞外abl1激酶活性检测试剂盒及其应用 |
CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
JP2024518426A (ja) | 2021-05-11 | 2024-05-01 | ノバルティス アーゲー | 投与レジメン |
CN117295725A (zh) * | 2021-05-28 | 2023-12-26 | 正大天晴药业集团股份有限公司 | 作为bcr-abl抑制剂的化合物 |
CN114149409B (zh) * | 2021-11-16 | 2024-03-22 | 中国药科大学 | 一种具有蛋白激酶抑制活性的(杂)芳基酰胺类化合物 |
CN116135851A (zh) * | 2021-11-17 | 2023-05-19 | 武汉众诚康健生物医药科技有限公司 | 一种芳香胺化合物及其应用 |
WO2023114759A2 (en) * | 2021-12-13 | 2023-06-22 | The Regents Of The University Of California | Abl inhibitors and uses thereof |
CN115109048B (zh) * | 2022-08-10 | 2023-12-08 | 中国药科大学 | 一种(杂)芳基酰胺类化合物 |
WO2024100212A1 (en) | 2022-11-10 | 2024-05-16 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
DE2845997A1 (de) | 1978-10-23 | 1980-04-30 | Bayer Ag | Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
KR890701567A (ko) | 1987-09-23 | 1989-12-21 | 쟝-쟈크 오가이, 프리돌린 클라우스너 | 헤테로사이클릭 화합물 |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
AU5620299A (en) | 1998-08-11 | 2000-03-06 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
WO2003039529A1 (en) | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US8030336B2 (en) | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
US20080167347A1 (en) | 2005-01-20 | 2008-07-10 | Shiongi & Co., Ltd. | Ctgf Expression Inhibitor |
WO2006120178A1 (en) | 2005-05-11 | 2006-11-16 | Novo Nordisk A/S | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
WO2007002441A1 (en) | 2005-06-24 | 2007-01-04 | Emory University | Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection |
SI1746097T1 (sl) | 2005-07-20 | 2010-05-31 | Aventis Pharma Sa | dihidropiridin kondenzirani heterocikli postopek za njihovo pripravo njihova uporaba in sestavki ki jih vsebujejo |
CN102861338A (zh) * | 2006-04-05 | 2013-01-09 | 诺瓦提斯公司 | 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合 |
WO2008021725A2 (en) | 2006-08-11 | 2008-02-21 | Smithkline Beecham Corporation | Chemical compounds |
EP2076513A1 (de) | 2006-10-20 | 2009-07-08 | Irm Llc | Zusammensetzungen und verfahren zur modulierung von c-kit- und pdgfr-rezeptoren |
EP2097380A1 (de) * | 2006-11-15 | 2009-09-09 | High Point Pharmaceuticals, LLC | Neue zur behandlung von obesitas und diabetes geeignete halogenalkylsulfonsubstituierte verbindungen |
US7851500B2 (en) * | 2007-01-05 | 2010-12-14 | Bristol-Myers Squibb Company | Aminopyrazole kinase inhibitors |
WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
WO2008124393A1 (en) | 2007-04-04 | 2008-10-16 | Irm Llc | Benzothiazole derivatives and their use as protein kinase inhibitors |
WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
EP2182935A1 (de) | 2007-08-02 | 2010-05-12 | F. Hoffmann-Roche AG | Verwendung von benzamid-derivaten zur behandlung von leiden des zentralen nervensystems |
RU2543620C2 (ru) | 2007-09-17 | 2015-03-10 | Эббви Бахамаз Лтд. | Производные урацила или тимина для лечения гепатита с |
KR20110017432A (ko) | 2008-06-11 | 2011-02-21 | 아이알엠 엘엘씨 | 말라리아의 치료에 유용한 화합물 및 조성물 |
US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
CN102548987B (zh) | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
JP2011057661A (ja) | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
EP2498607B1 (de) | 2009-11-13 | 2016-02-17 | Genosco | Kinase-inhibitoren |
JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
WO2011093684A2 (en) | 2010-01-29 | 2011-08-04 | Hanmi Holdings Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
CN102276500A (zh) * | 2011-05-05 | 2011-12-14 | 西安交通大学 | 水杨酰胺类抗肿瘤化合物及其合成方法和用途 |
PT2713722T (pt) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novos estabilizadores e moduladores do receptor glp-1 |
US9340537B2 (en) | 2012-05-15 | 2016-05-17 | Novatis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
TR201807023T4 (tr) | 2012-05-15 | 2018-06-21 | Novartis Ag | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. |
BR112014027181A2 (pt) | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 |
PL2900637T3 (pl) * | 2012-05-15 | 2018-01-31 | Novartis Ag | Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns |
-
2013
- 2013-05-09 TR TR2018/07023T patent/TR201807023T4/tr unknown
- 2013-05-09 NZ NZ701626A patent/NZ701626A/en unknown
- 2013-05-09 PT PT137306528T patent/PT2861579T/pt unknown
- 2013-05-09 EA EA201491824A patent/EA024391B1/ru not_active IP Right Cessation
- 2013-05-09 MA MA37519A patent/MA37519B1/fr unknown
- 2013-05-09 AU AU2013261127A patent/AU2013261127B2/en active Active
- 2013-05-09 MX MX2014013374A patent/MX359014B/es active IP Right Grant
- 2013-05-09 DK DK13730652.8T patent/DK2861579T5/da active
- 2013-05-09 GE GEAP201313621A patent/GEP201606532B/en unknown
- 2013-05-09 PE PE2014002006A patent/PE20150669A1/es not_active Application Discontinuation
- 2013-05-09 AP AP2014007992A patent/AP3613A/xx active
- 2013-05-09 ME MEP-2018-117A patent/ME03095B/de unknown
- 2013-05-09 SI SI201330997T patent/SI2861579T1/en unknown
- 2013-05-09 CN CN201380025539.6A patent/CN104302638B/zh active Active
- 2013-05-09 ES ES13730652.8T patent/ES2670601T3/es active Active
- 2013-05-09 RS RS20180497A patent/RS57177B1/sr unknown
- 2013-05-09 WO PCT/IB2013/053768 patent/WO2013171639A1/en active Application Filing
- 2013-05-09 JP JP2015512169A patent/JP6078639B2/ja active Active
- 2013-05-09 PE PE2020000185A patent/PE20210667A1/es unknown
- 2013-05-09 CA CA2868958A patent/CA2868958C/en active Active
- 2013-05-09 BR BR112014026383-3A patent/BR112014026383B1/pt active IP Right Grant
- 2013-05-09 KR KR1020147031773A patent/KR102091893B1/ko active Protection Beyond IP Right Term
- 2013-05-09 PE PE2016001014A patent/PE20161416A1/es unknown
- 2013-05-09 SG SG11201407152XA patent/SG11201407152XA/en unknown
- 2013-05-09 LT LTEP13730652.8T patent/LT2861579T/lt unknown
- 2013-05-09 EP EP13730652.8A patent/EP2861579B9/de active Active
- 2013-05-09 HU HUE13730652A patent/HUE039138T2/hu unknown
- 2013-05-09 CU CUP2014000131A patent/CU24265B1/es unknown
- 2013-05-09 MY MYPI2014703394A patent/MY169377A/en unknown
- 2013-05-09 PL PL13730652T patent/PL2861579T3/pl unknown
- 2013-05-13 US US13/892,769 patent/US8829195B2/en active Active
- 2013-05-15 AR ARP130101692A patent/AR091063A1/es active IP Right Grant
- 2013-05-15 JO JOP/2013/0150A patent/JO3453B1/ar active
- 2013-05-15 UY UY0001034811A patent/UY34811A/es active IP Right Grant
- 2013-05-15 TW TW102117263A patent/TWI560183B/zh active
- 2013-09-05 UA UAA201412051A patent/UA113208C2/uk unknown
-
2014
- 2014-07-31 US US14/448,363 patent/US20140343086A1/en not_active Abandoned
- 2014-09-29 ZA ZA2014/07065A patent/ZA201407065B/en unknown
- 2014-10-13 TN TN2014000427A patent/TN2014000427A1/fr unknown
- 2014-10-14 CL CL2014002757A patent/CL2014002757A1/es unknown
- 2014-11-06 IL IL235566A patent/IL235566A/en active IP Right Grant
- 2014-11-12 DO DO2014000256A patent/DOP2014000256A/es unknown
- 2014-11-13 PH PH12014502531A patent/PH12014502531A1/en unknown
- 2014-11-14 CO CO14252517A patent/CO7131380A2/es unknown
- 2014-11-14 CR CR20140519A patent/CR20140519A/es unknown
- 2014-11-14 SV SV2014004850A patent/SV2014004850A/es unknown
- 2014-11-14 GT GT201400253A patent/GT201400253A/es unknown
-
2015
- 2015-04-24 HK HK15103981.8A patent/HK1203495A1/xx unknown
-
2018
- 2018-05-03 HR HRP20180695TT patent/HRP20180695T1/hr unknown
- 2018-05-18 CY CY20181100518T patent/CY1120235T1/el unknown
-
2022
- 2022-10-20 FR FR22C1053C patent/FR22C1053I2/fr active Active
- 2022-10-25 HU HUS2200046C patent/HUS2200046I1/hu unknown
- 2022-10-25 NO NO2022043C patent/NO2022043I1/no unknown
- 2022-10-26 NL NL301201C patent/NL301201I2/nl unknown
- 2022-11-10 LT LTPA2022523C patent/LTPA2022523I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1053I2 (fr) | Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1 | |
FR2988609B1 (fr) | Formulation pour l'hormonotherapie | |
IT1403780B1 (it) | Dispositivo per l'infusione di farmaci. | |
BR112013009963A2 (pt) | "máquina de chá" | |
BR302012004271S1 (pt) | "configuração aplicada à cápsula" | |
HK1198929A1 (en) | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same 34- | |
BR302012004275S1 (pt) | "configuração aplicada à cápsula" | |
FR2993881B1 (fr) | Procede de preparation d'alkoxyphenol et d'alkoxyhydroxybenzaldehyde | |
ZA201508750B (en) | Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof | |
BR302012004274S1 (pt) | "configuração aplicada à cápsula" | |
FR2997627B1 (fr) | Produit de co-micronisation comprenant de l'ulipristal acetate | |
FR2986520B3 (fr) | Enrouleur de tuyau et agencement d'enrouleur de tuyau | |
BR302012004270S1 (pt) | "configuração aplicada à cápsula" | |
FR2958293B1 (fr) | Outils pour l'identification de ligands de lingo-1,lingo-2, lingo-3 et lingo-4, et utilisations | |
BR302012004273S1 (pt) | "configuração aplicada à cápsula" | |
IT1401289B1 (it) | Composti dotati di attivita' antiossidante nei confronti dei radicali liberi, e composizioni farmaceutiche e cosmetiche che li contengono | |
FR2984872B1 (fr) | Procede de preparation d'une composition talqueuse magnetique et composition talqueuse magnetique | |
IT1404927B1 (it) | Irroratrice per l'agricoltura. | |
BR302012004272S1 (pt) | "configuração aplicada à cápsula" | |
FR2957259B1 (fr) | Principe actif cosmetique raffermissant issu de piper nigrum, compositions cosmetiques l'incluant et utilisation | |
IT1402282B1 (it) | Albero espansibile perfezionato per l'avvolgimento di bobine multiple | |
FR2964101B1 (fr) | Procede de preparation d'adipate de di-alpha-methylbenzyle | |
FR2973002B1 (fr) | Sachet souple d'echantillon goutte-a-goutte, notamment pour parfum | |
LU92015B1 (fr) | Composition d'aliments pour animaux | |
UA24907S (uk) | Розгортка упаковки для цукерок «золота рибка» |